RxDoctor Payments Data

Nimish Patel, MD

Family Medicine · Charlotte, NCNPI 1710141668

Payments from drug & device makers

$4,561in general payments, 2019–2025

Across 210 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$931
  • AstraZeneca$616
  • AbbVie$551
  • Astellas Pharma US Inc$424
  • Lilly USA, LLC$373
  • Pfizer$213
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,30694%
  • Education$2556%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,561 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$88,080
Medicare patients
85
Services billed
1,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$53,029
JardianceEmpagliflozin46$45,771
EliquisApixaban38$44,068
FarxigaDapagliflozin Propanediol31$31,520
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$30,851
KerendiaFinerenone24$22,519
MyrbetriqMirabegron11$9,714
SymbicortBudesonide/Formoterol Fumarate19$6,647
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,943
Albuterol Sulfate HfaAlbuterol Sulfate72$2,214
Gabapentin99$2,079
Atorvastatin Calcium244$1,923
Rosuvastatin Calcium182$1,911
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$1,701
Levothyroxine Sodium190$1,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$616$69,01775 claims
Novo NordiskOzempic$931$53,02948 claims
Boehringer IngelheimJardiance$131$45,77146 claims
PfizerEliquis$213$44,06838 claims
BayerKerendia$208$22,51924 claims
Astellas Pharma US IncMyrbetriq$424$9,71411 claims
AbbVieSynthroid$551$1,07511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →